Technical Analysis for PTX - Prescient Therapeutics Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -4.65% | |
| Narrow Range Bar | Range Contraction | -4.65% | |
| Gapped Down | Weakness | -4.65% | |
| Oversold Stochastic | Weakness | -4.65% | |
| Stochastic Buy Signal | Bullish | -4.65% | |
| Gapped Down | Weakness | -4.65% | |
| Oversold Stochastic | Weakness | -4.65% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 3 days ago |
| Down 3% | 3 days ago |
| Possible NR7 | 3 days ago |
| 10 DMA Resistance | 3 days ago |
| Down 2% | 3 days ago |
Get this analysis on your stocks daily!
Prescient Therapeutics Ltd Description
Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Cancer Drugs Clinical Trial Pound Cancers Breast Cancer Tumor Oncology Leukemia Ovarian Cancer Promotion Multiple Myeloma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.105 |
| 52 Week Low | 0.037 |
| Average Volume | 560,377 |
| 200-Day Moving Average | 0.046 |
| 50-Day Moving Average | 0.043 |
| 20-Day Moving Average | 0.044 |
| 10-Day Moving Average | 0.043 |
| Average True Range | 0.002 |
| RSI (14) | 45.05 |
| ADX | 12.85 |
| +DI | 19.182 |
| -DI | 22.013 |
| Chandelier Exit (Long, 3 ATRs) | 0.043 |
| Chandelier Exit (Short, 3 ATRs) | 0.047 |
| Upper Bollinger Bands | 0.047 |
| Lower Bollinger Band | 0.040 |
| Percent B (%b) | 0.16 |
| BandWidth | 17.431 |
| MACD Line | -0.001 |
| MACD Signal Line | 0.000 |
| MACD Histogram | -0.0004 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.044 | ||||
| Resistance 3 (R3) | 0.044 | 0.044 | 0.044 | ||
| Resistance 2 (R2) | 0.044 | 0.043 | 0.044 | 0.043 | |
| Resistance 1 (R1) | 0.042 | 0.042 | 0.042 | 0.042 | 0.043 |
| Pivot Point | 0.042 | 0.042 | 0.042 | 0.042 | 0.042 |
| Support 1 (S1) | 0.040 | 0.041 | 0.040 | 0.040 | 0.039 |
| Support 2 (S2) | 0.040 | 0.040 | 0.040 | 0.039 | |
| Support 3 (S3) | 0.038 | 0.040 | 0.039 | ||
| Support 4 (S4) | 0.038 |
